Relapsed/Refractory

Criteria to qualify for study: Drug used in study:
  • Phase 1a Escalation
  • Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis
  • ANC > 1.5 / PLT > 75
  • HGB > 10 in absence of transfusion and growth factors for at least 28 days /
  • ECOG 0,1 or 2
  • Relapsed of Refractory

Hemref 43 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed of Refractory Hematologic Malignancies